Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
Frontiers in Immunology ; 13:1033770, 2022.
Article in English | MEDLINE | ID: covidwho-2198880

ABSTRACT

Background: Although SARS-CoV-2 vaccines have proven effective in eliciting a protective immune response in healthy individuals, their ability to induce a durable immune response in immunocompromised individuals remains poorly understood. Primary antibody deficiency (PAD) syndromes are among the most common primary immunodeficiency disorders in adults and are characterized by hypogammaglobulinemia and impaired ability to mount robust antibody responses following infection or vaccination.

2.
Heart Lung and Circulation ; 30:S322-S323, 2021.
Article in English | EMBASE | ID: covidwho-1747967

ABSTRACT

Background: Transcatheter aortic valve implantation (TAVI) is now guideline treatment for severe aortic stenosis in patients over the age of 80 years. Objective: We report the initial experience of the first 50 patients for the Tasmanian TAVI Service at the Royal Hobart Hospital established during the COVID-19 pandemic. Methods: The records of patients undergoing TAVI with a balloon-expandable device between June 2020 and March 2021 at the Royal Hobart Hospital were reviewed. We report the procedural success and outcome, including major adverse events and haemodynamic results at the 30-day follow-up. Results: Mean age was 83.2±0.7 and mean EuroSCORE II and Society of Thoracic Surgeons’ scores were 5.6%±0.4% and 6.2%±1.0%, respectively;18% had undergone prior cardiac surgery. Successful transfemoral deployment of the valve was achieved in all patients. The cumulative stroke and mortality rates at 30 days were 0%. The minor vascular complication rate was 3.8%, with no major vascular complications, as per the Valve Academic Research Consortium-2 (VARC-2) criteria. No/trivial paravalvular aortic regurgitation (pAR) was observed in 79%, with 21% mild pAR. The mean AVA (cm2) increased from 0.73 to 2.1, with a subsequent mean reduction in mean gradient (mmHg) from 40 to 10. Post-TAVI permanent pacemaker rate was 12%. Median length of hospital stay was 1.48 days. Conclusion: TAVI is now readily accessible locally for Tasmanians deemed suitable for intervention as per the state-wide heart team. Early results are excellent and indicate that TAVI is being used appropriately, according to current national and international guidelines.

3.
Pharmacoepidemiology and Drug Safety ; 30:16-17, 2021.
Article in English | Web of Science | ID: covidwho-1353132
SELECTION OF CITATIONS
SEARCH DETAIL